As a result, SHR-A1403 demonstrated strong preclinical anti-tumor efficacy in pancreatic cancer, indicating its potential use as a c-MET-targeted antibody-drug conjugate treatment for PDAC in clinical practice (104). The gene discussed is MET; the disease is neoplasm.